Description: In-vitro diagnostics company introducing ProNephro AKI™ (NGAL), the first FDA-cleared test for pediatric acute kidney injury risk assessment.
Pro Nephro AKI (NGAL) is now FDA-Cleared READ MORE
The first FDA-cleared test for pediatric acute kidney injury risk assessment
AKI is a silent epidemic among hospitalized patients—affecting more than 1 in 4 children i and 1 in 5 adults. ii Earlier AKI risk assessment can inform treatment decisions, minimize unnecessary intervention, and improve patient outcomes.